BioZorb Surgical Marker Enhances Breast Cancer Patients’ Outcome

BioZorb Surgical Marker Enhances Breast Cancer Patients’ Outcome
biozorbOne of Scottsdale-based Arizona Breast Cancer Specialists' researchers, Robert Kuske, MD, presented data at the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) held September 14-17 that suggests a new surgical marker can increase the preciseness of delivered radiation therapy by radiation oncologists to breast cancer patients. The presentation focused on the BioZorb™ Tissue Marker from Focal Therapeutics, Inc. "Like many great innovations, the design of the new marker is relatively simple and its effects are profound," said Dr. Kuske, MD, in a press release provided by the company. "The reduction in treatment volumes means that with this marker, women have far less risk of damage to healthy tissue during treatment, and that they can expect better cosmetic results." These findings were made through two main studies. One study documented 51 cases of physician's clinical experience with BioZorb. Using the surgical marker enabled smaller volumes of radiation treatment and doses in patients receiving either boost or accelerated partial breast irradiation (APBI), a technique pioneered by Dr. Kuske to reduce the time of treatment from six weeks to five days for patients with select types of early-stage breast cancer. Ano
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.